Good morning, you're listening to Markets Desk.
Partners Group took a hit in the first half of two thousand twenty six, with the Swiss private equity giant reporting a decline in net income against the prior year period. The results are weighing on sentiment in European markets more broadly, where stocks are set to drift lower at the open amid persistent inflation concerns following a soft session on Wall Street overnight. Traders are watching closely to see whether that inflation anxiety translates into any shift in rate expectations heading into the back half of the year.
Shifting to healthcare, Biogen and Eisai received a meaningful regulatory tailwind as Canada's Drug Agency issued a final recommendation supporting public reimbursement of LEQEMBI, their Alzheimer's treatment lecanemab. The drug targets patients with mild cognitive impairment or early-stage dementia, and public reimbursement approval in Canada opens a significant new payer channel. For Biogen specifically, this adds commercial momentum to a therapy that has faced a long road to broad market access across multiple jurisdictions.
And on the geopolitical front, Ukraine's air force is reporting that Russia increased jet-powered Shahed drone attacks by five times between June and July, with roughly one thousand five hundred of the faster, higher-flying Geran variants launched last month alone. The escalation raises fresh questions about air defense resource allocation and the durability of current countermeasures.
That's the tape. Markets Desk, signing off the floor.
